Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results
Neurocrine Biosciences (Nasdaq: NBIX) has announced its schedule for the third quarter 2024 financial results conference call and webcast. The event is set for October 30, 2024, with the press release at 4:00 a.m. PT and the conference call at 5:00 a.m. PT. Investors can access the webcast on the company's website, with a replay available for approximately one month.
Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company dedicated to developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders. The company's portfolio includes FDA-approved treatments for tardive dyskinesia, Huntington's disease-associated chorea, endometriosis, and uterine fibroids. They also have multiple compounds in mid- to late-phase clinical development across their core therapeutic areas.
Neurocrine Biosciences (Nasdaq: NBIX) ha annunciato il programma per la conferenza sui risultati finanziari del terzo trimestre 2024 e relativa diretta web. L'evento è previsto per 30 ottobre 2024, con il comunicato stampa alle 4:00 a.m. PT e la conferenza alle 5:00 a.m. PT. Gli investitori possono accedere alla diretta web sul sito dell'azienda, con una riproduzione disponibile per circa un mese.
Neurocrine Biosciences è una azienda biofarmaceutica focalizzata sulle neuroscienze impegnata nello sviluppo di trattamenti per disturbi neurologici, neuroendocrini e neuropsichiatrici. Il portafoglio dell'azienda include trattamenti approvati dalla FDA per la discinesia tardiva, la corea associata alla malattia di Huntington, l'endometriosi e i fibromi uterini. Hanno inoltre diversi composti in sviluppo clinico dalle fasi intermedie a quelle avanzate nei loro principali ambiti terapeutici.
Neurocrine Biosciences (Nasdaq: NBIX) ha anunciado su calendario para la conferencia de resultados financieros del tercer trimestre de 2024 y la transmisión web. El evento está programado para el 30 de octubre de 2024, con el comunicado de prensa a las 4:00 a.m. PT y la conferencia a las 5:00 a.m. PT. Los inversores pueden acceder a la transmisión web en el sitio web de la empresa, con una repetición disponible por aproximadamente un mes.
Neurocrine Biosciences es una empresa biofarmacéutica centrada en la neurociencia dedicada al desarrollo de tratamientos para trastornos neurológicos, neuroendocrinos y neuropsiquiátricos. El portafolio de la empresa incluye tratamientos aprobados por la FDA para la discinesia tardía, la corea asociada a la enfermedad de Huntington, la endometriosis y los fibromas uterinos. También tienen múltiples compuestos en desarrollo clínico de fase media a avanzada en sus áreas terapéuticas principales.
신경내분비학 생명과학(나스닥: NBIX)이 2024년 3분기 재무 결과 회의 및 웹캐스트 일정을 발표했습니다. 이 행사는 2024년 10월 30일에 예정되어 있으며, 보도 자료는 오전 4:00 PT에 발표되고 회의는 오전 5:00 PT에 진행됩니다. 투자자들은 회사 웹사이트에서 웹캐스트에 접근할 수 있으며, 약 한 달 동안 재생 가능합니다.
신경내분비학 생명과학은 신경과학에 중점을 둔 생명공학 제약회사로, 신경학적, 신경내분비, 신경정신 장애 치료제를 개발하는 데 전념하고 있습니다. 이 회사의 포트폴리오에는 지연성 운동장애, 헌팅턴병 관련 무도병, 자궁내막증 및 자궁근종에 대한 FDA 승인 치료제가 포함되어 있습니다. 그리고 그들은 주요 치료 영역 내에서 중기 및 후기 임상 개발에 있는 여러 화합물을 보유하고 있습니다.
Neurocrine Biosciences (Nasdaq: NBIX) a annoncé son calendrier pour la conférence téléphonique et le webinaire concernant les résultats financiers du troisième trimestre 2024. L'événement est prévu pour le 30 octobre 2024, avec le communiqué de presse à 4h00 PT et la conférence téléphonique à 5h00 PT. Les investisseurs peuvent accéder au webinaire sur le site de l'entreprise, avec une rediffusion disponible pendant environ un mois.
Neurocrine Biosciences est une entreprise biopharmaceutique axée sur les neurosciences dédiée au développement de traitements pour les troubles neurologiques, neuroendocriniens et neuropsychiatriques. Le portefeuille de l'entreprise comprend des traitements approuvés par la FDA pour la dyskinésie tardive, la chorée associée à la maladie de Huntington, l'endométriose et les fibromes utérins. Ils ont également plusieurs composés en développement clinique dans les phases intermédiaire à avancée dans leurs domaines thérapeutiques principaux.
Neurocrine Biosciences (Nasdaq: NBIX) hat seinen Zeitplan für die Telefonkonferenz und den Webcast zu den finanziellen Ergebnissen des 3. Quartals 2024 bekannt gegeben. Die Veranstaltung ist für den 30. Oktober 2024 angesetzt, mit der Pressemitteilung um 4:00 Uhr PT und der Telefonkonferenz um 5:00 Uhr PT. Investoren können den Webcast auf der Website des Unternehmens abrufen, mit einer Wiederholung, die etwa einen Monat lang verfügbar ist.
Neurocrine Biosciences ist ein biopharmazeutisches Unternehmen mit Schwerpunkt Neurowissenschaften, das sich der Entwicklung von Behandlungen für neurologische, neuroendokrine und neuropsychiatrische Störungen widmet. Das Portfolio des Unternehmens umfasst von der FDA genehmigte Behandlungen für tardive Dyskinesie, die Chorea im Zusammenhang mit der Huntington-Krankheit, Endometriose und Uterusmyome. Sie haben auch mehrere Verbindungen in der klinischen Entwicklung in der mittleren bis späten Phase in ihren wichtigsten Therapiegebieten.
- Neurocrine Biosciences has FDA-approved treatments in its portfolio
- The company has a robust pipeline with multiple compounds in mid- to late-phase clinical development
- None.
Conference Call and Webcast Scheduled for Wednesday, October 30
The schedule for the press release and conference call / webcast is as follows:
• Q3 2024 Press Release: | October 30, 2024 at 4:00 a.m. PT / 7:00 a.m. ET |
• Q3 2024 Conference Call: | October 30, 2024 at 5:00 a.m. PT / 8:00 a.m. ET |
• Domestic Dial-In Number: | 800-225-9448 |
• International Dial-In Number: | 203-518-9708 |
• Conference ID: | NBIX |
The webcast can also be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X (Formerly Twitter) and Facebook. (*in collaboration with AbbVie)
NEUROCRINE BIOSCIENCES, NEUROCRINE, and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc. The Neurocrine logo is a trademark of Neurocrine Biosciences, Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-of-third-quarter-2024-financial-results-302271930.html
SOURCE Neurocrine Biosciences, Inc.
FAQ
When will Neurocrine Biosciences (NBIX) release its Q3 2024 financial results?
What time is the Neurocrine Biosciences (NBIX) Q3 2024 earnings conference call?
How can investors access Neurocrine Biosciences' (NBIX) Q3 2024 earnings webcast?
What are the main therapeutic areas Neurocrine Biosciences (NBIX) focuses on?
